Watts Water Technologies Down Over 5%, on Pace for Largest Percent Decrease Since November 2025 -- Data Talk
Dow Jones2026/10/28 17:30Watts Water Technologies, Inc. Class A (WTS) is currently at $342.76, down $18.62 or 5.15%
--Would be lowest close since July 29, 2026, when it closed at $336.15
--On pace for largest percent decrease since Nov. 6, 2025, when it fell 6.62%
--Currently down two consecutive days; down 6.79% over this period
--Worst two day stretch since the two days ending April 4, 2025, when it fell 10.08%
--Down 3.22% month-to-date; on pace for worst month since July 2026, when it fell 11.66%
--Up 24.18% year-to-date
--Down 12.61% from its all-time closing high of $392.23 on Aug. 7, 2026
--Up 25.49% from 52 weeks ago (Oct. 29, 2025), when it closed at $273.15
--Down 12.61% from its 52-week closing high of $392.23 on Aug. 7, 2026
--Up 30.06% from its 52-week closing low of $263.55 on Nov. 6, 2025
--Traded as low as $342.65; lowest intraday level since Oct. 8, 2026, when it hit $340.40
--Down 5.18% at today's intraday low; largest intraday percent decrease since Oct. 7, 2026, when it fell as much as 5.31%
All data as of 1:25:50 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 28, 2026 13:30 ET (17:30 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

The 160 Threshold Under Threat Again! Yen Nears "Intervention Red Line," Tokyo May Spend Money Again to Rescue the Currency
The Japanese yen is approaching the 1 USD = 160 JPY level. Atsushi Mimura commented that the movement is "too fast." The US-Japan interest rate gap may widen further, and Japanese officials have hinted at being ready to intervene again.
Blackstone (BX.US) injects up to $1.5 billion, providing fresh ammunition for Pfizer (PFE.US) in the weight-loss drug race
Pfizer announced on Wednesday that it has reached an agreement with Blackstone to obtain up to $1.5 billions in funding to support the development of its experimental monthly obesity treatment drug.